** Shares of Ajanta Pharma AJPH.NS rise 2.4% to 2,626.30 rupees
** Jefferies starts coverage on AJPH with 'buy' and price target of 2,850 rupees
** Brokerage expects AJPH to further improve its market positioning and achieve mid-teens revenue growth for branded generics segment
** Co expected to achieve 200 bps margin expansion to 29.5% on rising contribution from branded generic markets - Jefferies
** Brokerage sees limited impact from potential US reciprocal tariffs for AJPH margins as US margins are much lower than company avg
** Analysts, on average, rate AJPH at "buy", median PT is 2,990 rupees - data compiled by LSEG
** AJPH down ~10% in 2025 after gaining 40.7% in 2024
(Reporting by Vijay Malkar)
((VijayDattaram.Malkar@thomsonreuters.com;))